Djillali Annane1, Stephen M Pastores2, Bram Rochwerg3, Wiebke Arlt4, Robert A Balk5, Albertus Beishuizen6, Josef Briegel7, Joseph Carcillo8, Mirjam Christ-Crain9, Mark S Cooper10, Paul E Marik11, Gianfranco Umberto Meduri12, Keith M Olsen13, Sophia C Rodgers14, James A Russell15, Greet Van den Berghe16. 1. General ICU Department, Raymond Poincaré Hospital (APHP), Health Science. 2. Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Division of Critical Care, Department of Medicine, McMaster University, Hamilton, ON, Canada. 4. Institute of Metabolism and Systems Research (IMSR), University of Birmingham and Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham, UK. 5. Division of Pulmonary and Critical Care Medicine, Rush University Medical Center, Chicago, IL, USA. 6. Department of Intensive Care Medicine, Medisch Spectrum Twente, Enschede, The Netherlands. 7. Anesthesiology and Critical Care Medicine, Klinik für Anästhesiologie, Klinikum der Universität, Munich, Germany. 8. Department of Critical Care Medicine and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 9. Department of Endocrinology, Diabetology and Metabolism, Clinical Research, University Hospital Basel, Basel, Switzerland. 10. Department of Endocrinology, Concord Hospital, University of Sidney, Sidney, NSW, Australia. 11. Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA, USA. 12. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Memphis Veterans Affairs Medical Center, Memphis, TN, USA. 13. College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 14. Clinical Adjunct Faculty, University of New Mexico and Sandoval Regional Medical Center, Albuquerque, NM, USA. 15. Division of Critical Care Medicine, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada. 16. Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven University and Hospitals, Louvain, Belgium.
Abstract
OBJECTIVE: To update the 2008 consensus statements for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in adult and pediatric patients. PARTICIPANTS: A multispecialty task force of 16 international experts in critical care medicine, endocrinology, and guideline methods, all of them members of the Society of Critical Care Medicine and/or the European Society of Intensive Care Medicine. DESIGN/ METHODS: The recommendations were based on the summarized evidence from the 2008 document in addition to more recent findings from an updated systematic review of relevant studies from 2008 to 2017 and were formulated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. The strength of each recommendation was classified as strong or conditional, and the quality of evidence was rated from high to very low based on factors including the individual study design, the risk of bias, the consistency of the results, and the directness and precision of the evidence. Recommendation approval required the agreement of at least 80% of the task force members. RESULTS: The task force was unable to reach agreement on a single test that can reliably diagnose CIRCI, although delta cortisol (change in baseline cortisol at 60 min of < 9 μg/dL) after cosyntropin (250 μg) administration and a random plasma cortisol of < 10 μg/dL may be used by clinicians. We suggest against using plasma-free cortisol or salivary cortisol level over plasma total cortisol (conditional, very low quality of evidence). For treatment of specific conditions, we suggest using IV hydrocortisone < 400 mg/day for ≥ 3 days at full dose in patients with septic shock that is not responsive to fluid and moderate- to high-dose vasopressor therapy (conditional, low quality of evidence). We suggest not using corticosteroids in adult patients with sepsis without shock (conditional recommendation, moderate quality of evidence). We suggest the use of IV methylprednisolone 1 mg/kg/day in patients with early moderate to severe acute respiratory distress syndrome (PaO2/FiO2 < 200 and within 14 days of onset) (conditional, moderate quality of evidence). Corticosteroids are not suggested for patients with major trauma (conditional, low quality of evidence). CONCLUSIONS: Evidence-based recommendations for the use of corticosteroids in critically ill patients with sepsis and septic shock, acute respiratory distress syndrome, and major trauma have been developed by a multispecialty task force.
OBJECTIVE: To update the 2008 consensus statements for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in adult and pediatric patients. PARTICIPANTS: A multispecialty task force of 16 international experts in critical care medicine, endocrinology, and guideline methods, all of them members of the Society of Critical Care Medicine and/or the European Society of Intensive Care Medicine. DESIGN/ METHODS: The recommendations were based on the summarized evidence from the 2008 document in addition to more recent findings from an updated systematic review of relevant studies from 2008 to 2017 and were formulated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. The strength of each recommendation was classified as strong or conditional, and the quality of evidence was rated from high to very low based on factors including the individual study design, the risk of bias, the consistency of the results, and the directness and precision of the evidence. Recommendation approval required the agreement of at least 80% of the task force members. RESULTS: The task force was unable to reach agreement on a single test that can reliably diagnose CIRCI, although delta cortisol (change in baseline cortisol at 60 min of < 9 μg/dL) after cosyntropin (250 μg) administration and a random plasma cortisol of < 10 μg/dL may be used by clinicians. We suggest against using plasma-free cortisol or salivary cortisol level over plasma total cortisol (conditional, very low quality of evidence). For treatment of specific conditions, we suggest using IV hydrocortisone < 400 mg/day for ≥ 3 days at full dose in patients with septic shock that is not responsive to fluid and moderate- to high-dose vasopressor therapy (conditional, low quality of evidence). We suggest not using corticosteroids in adult patients with sepsis without shock (conditional recommendation, moderate quality of evidence). We suggest the use of IV methylprednisolone 1 mg/kg/day in patients with early moderate to severe acute respiratory distress syndrome (PaO2/FiO2 < 200 and within 14 days of onset) (conditional, moderate quality of evidence). Corticosteroids are not suggested for patients with major trauma (conditional, low quality of evidence). CONCLUSIONS: Evidence-based recommendations for the use of corticosteroids in critically illpatients with sepsis and septic shock, acute respiratory distress syndrome, and major trauma have been developed by a multispecialty task force.
Authors: João João Mendes; José Artur Paiva; Filipe Gonzalez; Paulo Mergulhão; Filipe Froes; Roberto Roncon; João Gouveia Journal: Rev Bras Ter Intensiva Date: 2022-01-24
Authors: Bruno M Tomazini; Israel S Maia; Alexandre B Cavalcanti; Otavio Berwanger; Regis G Rosa; Viviane C Veiga; Alvaro Avezum; Renato D Lopes; Flavia R Bueno; Maria Vitoria A O Silva; Franca P Baldassare; Eduardo L V Costa; Ricardo A B Moura; Michele O Honorato; Andre N Costa; Lucas P Damiani; Thiago Lisboa; Letícia Kawano-Dourado; Fernando G Zampieri; Guilherme B Olivato; Cassia Righy; Cristina P Amendola; Roberta M L Roepke; Daniela H M Freitas; Daniel N Forte; Flávio G R Freitas; Caio C F Fernandes; Livia M G Melro; Gedealvares F S Junior; Douglas Costa Morais; Stevin Zung; Flávia R Machado; Luciano C P Azevedo Journal: JAMA Date: 2020-10-06 Impact factor: 56.272
Authors: Ben Gibbison; Daniel M Keenan; Ferdinand Roelfsema; Jon Evans; Kirsty Phillips; Chris A Rogers; Gianni D Angelini; Stafford L Lightman Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958